2015 med tech R&D budget: $688 million
Change from 2014 budget ($588 million): 17%
Percent of 2015 segment sales ($3.35 billion): 20%
Danaher made strides in R&D after deciding to split into two publicly traded companies last year. In May 2015, the lab equipment provider said that it would maintain its life science and technology units under the name Danaher. The company also created a smaller company comprising its industrial businesses called Fortive, which it established this year.
The move came after Danaher picked up filtration and purification system maker Pall for $13.8 billion. The deal gave Danaher “access to the capital necessary to pursue organic and inorganic growth opportunities,” Danaher CEO Thomas Joyce Jr. said at the time.
One potential growth area is biopharma. Danaher has said that it wants to leverage Pall’s offerings to life science customers. A good chunk of Pall’s revenue came from sales of life science products to biopharma and medical markets.
Earlier this year, Danaher considered purchasing drug-delivery capsule maker Capsugel after the company said it was mulling a sale or IPO. Capsugel’s products include Coni-Snap Sprinkle Capsules for patients who have trouble swallowing and DuoCap Capsules for dual release.
Capsugel eyeing IPO or sale for $5B+
Danaher tags its industrial unit with the name 'Fortive' as part of the company split
Danaher buys water-systems maker for $13.8B, will split into two companies